Published in Cancer Res on July 01, 1996
DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol (1998) 4.61
Roles for Nkx3.1 in prostate development and cancer. Genes Dev (1999) 4.30
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Long-range enhancers on 8q24 regulate c-Myc. Proc Natl Acad Sci U S A (2010) 2.54
Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Hum Genet (2008) 2.41
Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol (2010) 2.38
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer (1999) 2.34
Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet (1999) 2.12
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol (1998) 1.97
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol (1999) 1.42
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer (2001) 1.37
Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol (2001) 1.25
A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Mol Cell Biol (1998) 1.24
A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am J Hum Genet (2001) 1.16
BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta (2008) 1.12
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer (2001) 1.07
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol (1997) 1.06
Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer (2004) 1.06
Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiol Biomarkers Prev (2010) 1.03
Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am (2010) 1.02
From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization. Am J Hum Genet (1998) 0.98
DNA copy number changes in development and progression in leiomyosarcomas of soft tissues. Am J Pathol (1998) 0.97
Calling amplified haplotypes in next generation tumor sequence data. Genome Res (2011) 0.95
Mathematical modeling of prostate cancer progression in response to androgen ablation therapy. Proc Natl Acad Sci U S A (2011) 0.95
TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene (2014) 0.94
SPOP mutation leads to genomic instability in prostate cancer. Elife (2015) 0.93
Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single-copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. Am J Pathol (1997) 0.92
Human RecQL4 helicase plays critical roles in prostate carcinogenesis. Cancer Res (2010) 0.91
Power to detect selective allelic amplification in genome-wide scans of tumor data. Bioinformatics (2009) 0.91
Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer. Twin Res Hum Genet (2010) 0.87
Krüppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol (2003) 0.86
Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer's disease brain and correlates with neurofibrillary tangle pathology. J Alzheimers Dis (2014) 0.82
Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations. Am J Pathol (1999) 0.81
Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer. Sci Rep (2015) 0.81
The impact of genomic alterations on the transcriptome: a prostate cancer cell line case study. Chromosome Res (2006) 0.80
Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells. Biosci Rep (2013) 0.79
Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study. Genes Cancer (2012) 0.79
Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer. Mol Cancer Ther (2014) 0.78
Changes of transthyretin and clusterin after androgen ablation therapy and correlation with prostate cancer malignancy. Transl Oncol (2012) 0.77
The inhibitory effects of NKX3.1 on IGF-1R expression and its signalling pathway in human prostatic carcinoma PC3 cells. Asian J Androl (2011) 0.75
Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer. Sci Rep (2017) 0.75
FRACTIONATION OF SERUM PROTEINS IN HYPERPROTEINEMIA, WITH SPECIAL REFERENCE TO MULTIPLE MYELOMA. J Clin Invest (1941) 11.64
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63
THE RELATION OF CEPHALIN FLOCCULATION AND COLLOIDAL GOLD REACTIONS TO THE SERUM PROTEINS. J Clin Invest (1943) 7.05
AN ELECTROPHORETIC STUDY OF THE PROTEIN COMPONENTS IN CEREBROSPINAL FLUID AND THEIR RELATIONSHIP TO THE SERUM PROTEINS. J Clin Invest (1942) 6.90
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
MECHANISM OF THE POSITIVE CEPHALIN-CHOLESTEROL FLOCCULATION REACTION IN HEPATITIS. J Clin Invest (1945) 5.81
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst (1995) 3.96
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn (2000) 3.59
Mandatory second opinion surgical pathology at a large referral hospital. Cancer (1999) 3.40
The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology (1996) 3.26
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol (1998) 3.10
DNA content and DNA-based centromeric index of the 24 human chromosomes. Science (1973) 3.08
Telepathology diagnosis of prostrate needle biopsies. Hum Pathol (1997) 2.99
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol (1996) 2.97
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res (1999) 2.96
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA (1997) 2.73
Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol (2000) 2.73
Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol (2001) 2.68
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res (1992) 2.55
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (1994) 2.53
Chromosome measurement and sorting by flow systems. Proc Natl Acad Sci U S A (1975) 2.37
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res (1994) 2.34
Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology (1999) 2.32
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology (2011) 2.28
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology (2001) 2.27
SIGNIFICANCE OF CEPHALIN-CHOLESTEROL FLOCCULATION TEST IN MALARIAL FEVER. J Clin Invest (1945) 2.26
A prospective controlled trial of early postoperative oral intake following major abdominal gynecologic surgery. Gynecol Oncol (1997) 2.23
Evidence for increased in vivo mutation and somatic recombination in Bloom's syndrome. Proc Natl Acad Sci U S A (1989) 2.22
Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A (1990) 2.22
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2007) 2.20
Common properties of the oncogenic RNA viruses (oncornaviruses). Virology (1970) 2.20
Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol (2000) 2.19
Search for a human breast cancer virus. Nature (1971) 2.14
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
Primary renal synovial sarcoma: molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney. Am J Surg Pathol (2000) 2.05
Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol (1998) 2.03
Mammary tumor viruses. Adv Cancer Res (1979) 2.03
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst (2000) 1.99
Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol (1997) 1.97
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res (1993) 1.96
Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol (1994) 1.89
Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res (1996) 1.87
Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol (2001) 1.87
Murine mammary tumor virus: characterization of infection of nonmurine cells. J Virol (1976) 1.87
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol (1994) 1.87
Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol (1997) 1.86
Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol (2000) 1.85
Leiomyosarcoma of the paratesticular region: a clinicopathologic study. Am J Surg Pathol (2001) 1.84
Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res (1996) 1.83
Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology (2001) 1.83
Fungal sinusitis: diagnosis with CT and MR imaging. Radiology (1988) 1.82
Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology (1999) 1.82
Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res (2000) 1.82
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol (2001) 1.81
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol (1988) 1.81
An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res (2000) 1.81
Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA (1997) 1.80
Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor. J Urol (2001) 1.77
Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology (1994) 1.75
Low-grade myxoid renal epithelial neoplasms with distal nephron differentiation. Hum Pathol (2001) 1.74
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72
The relationship between maternal age and uterine dysfunction: a continuous effect throughout reproductive life. Am J Obstet Gynecol (2000) 1.72
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71